Reflections on early stopping of a clinical trial
- 30 September 2006
- journal article
- editorial
- Published by Elsevier in American Heart Journal
- Vol. 152 (3) , 407-409
- https://doi.org/10.1016/j.ahj.2006.06.006
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overviewAmerican Heart Journal, 2006
- Stopping trials early for commercial reasons: the risk–benefit relationship as a moral compass: Table 1Journal of Medical Ethics, 2005
- Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary interventionAmerican Heart Journal, 2005
- Arthritis Medicines and Cardiovascular Events—“House of Coxibs”JAMA, 2005
- Clinical Trial RegistrationJAMA, 2004
- Stopping Medical Research to Save MoneyJAMA, 2003
- Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) TrialJAMA, 2003
- Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility Commentary: Early discontinuation violates Helsinki principlesBMJ, 2001
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993